Novo Nordisk Cuts GLP-1 Prices by 50% and Seals $2.1 B Vivtex Deal
Novo Nordisk will slash U.S. list prices for Wegovy, Ozempic and Rybelsus by up to 50% to $675 per month starting 2027 to expand patient access. It also sealed a partnership with Vivtex to develop oral obesity and diabetes biologics, with upfront and milestone payments up to $2.1 billion.
1. GLP-1 Price Reduction Plan
Novo Nordisk plans to cut U.S. list prices for its leading GLP-1 therapies—Wegovy, Ozempic and Rybelsus—by up to 50%, fixing a uniform price of $675 per month from 2027 to improve affordability and drive broader adoption among high-deductible plan patients.
2. Vivtex Collaboration Details
The company entered a strategic alliance with Vivtex Corporation to leverage its AI-enabled gastrointestinal screening and oral drug-delivery platform for next-generation oral biologic treatments in obesity and diabetes, with Vivtex eligible for upfront, research and milestone payments totaling as much as $2.1 billion plus tiered royalties.
3. Analyst View on Competitive Impact
An equity research team projects these price cuts will exert only limited pressure on Eli Lilly’s existing weight-loss drug franchise, indicating that market share shifts among GLP-1 competitors may be more gradual than feared.